glp-1 gip medication long term effects muscle loss Glucagon-like peptide-1 receptor agonists and mass GLP-1 Medications Infographic | Medidex

Canadian Employer Plans Covering GLP-1s for Weight Loss Have Nearly Doubled Data from the International Foundation of Employee Benefit Plans (IFEBP) 2025 Pulse Survey shows a significant shift in Canadian employer attitudes toward GLP-1 coverage: 31% of employer plans now cover GLP-1s for weight loss (up from 17% in 2024) 56% cover for diabetes only (down from 66% in 2024) 20% of diabetes-only plans are considering adding obesity coverage Provincial public drug plans still cover semaglutide only for type 2 diabetes not for weight loss

A case for screening real-world data for collateral drug benefits: Glucagon-like peptide 1 receptor agonists and bile acid diarrhea

Lancet Diabetes Endocrinol 2014;2:30e7

Experimental investigations have demonstrated that cholangiocytes are sensitive to GLP-1 and respond with augmented proliferation, potentially increasing the risk of duct obstruction [47,48]

This means you get an expert to manage side effects and create a sustainable weight loss plan that works for your body

there are still concerns with weight gain after stopping these medications, so more research is needed in order to understand the main reasons for the weight gain. Research is now focused on trying to figure out more about how these drugs work